{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:25:38Z","timestamp":1749947138539},"reference-count":12,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:title>AIMS<\/jats:title><jats:p>To develop a population pharmacokinetic model for maraviroc, a noncompetitive CCR5 antagonist, after oral administration of tablets to healthy volunteers and asymptomatic HIV\u2010infected subjects and to quantify the inherent variability and influence of covariates on the parameters of the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Rich pharmacokinetic data available from 15 studies in healthy volunteers (<jats:italic>n<\/jats:italic>\u2003=\u2003365) and two studies in asymptomatic HIV\u2010infected subjects (<jats:italic>n<\/jats:italic>\u2003=\u200348) were analysed using NONMEM. Maraviroc was administered as single or multiple oral tablet doses under fasted and fed conditions. Doses ranged from 100 to 1800\u2003mg\u2003day<jats:sup>\u22121<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A two\u2010compartment model parameterized to separate out absorption and clearance components on bioavailability was used. Absorption was described by a lagged first\u2010order process. A sigmoid <jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub> model described the effect of dose on absorption. A visual predictive check and nonparametric bootstrap evaluation confirmed that the model was a good description of the data. Typical CL, <jats:italic>V<\/jats:italic><jats:sub>c<\/jats:sub> and V<jats:sub>p<\/jats:sub> values for a 30\u2010year\u2010old non\u2010Asian are 51.5\u2003l\u2003h<jats:sup>\u22121<\/jats:sup>, 132\u2003l and 277\u2003l, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>For the typical non\u2010Asian subject, fasted bioavailability increased asymptotically with dose from 24% at 100\u2003mg to 33% at 600\u2003mg. A high\u2010fat meal taken with maraviroc reduced exposure by 43% for a 100\u2010mg dose to approximately 25% at doses of 600\u2003mg. The typical Asian subject had a 26.5% higher AUC than the typical non\u2010Asian subject irrespective of dose, a difference not considered to be clinically relevant. None of the other covariates tested had any clinically relevant effects on exposure.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2008.03139.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T04:04:35Z","timestamp":1205208275000},"page":"76-85","source":"Crossref","is-referenced-by-count":28,"title":["A population pharmacokinetic meta\u2010analysis of maraviroc in healthy volunteers and asymptomatic HIV\u2010infected subjects"],"prefix":"10.1111","volume":"65","author":[{"given":"Phylinda L. S.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Weatherley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6468(05)43007-6"},{"key":"e_1_2_6_3_2","unstructured":"WeatherleyB McFadyenL MilliganP.Population analysis of maraviroc phase 1 noncompartmental pharmacokinetic data. In:15th Meeting of the Population Approach Group Europe. 2006 June 14\u201316; Brussels Belgium."},{"key":"e_1_2_6_4_2","unstructured":"MuirheadG PozniakA GazzardB NelsonM MoyleG RidgwayC Taylor\u2010WorthR RussellD. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK\u2010427\u2003857 in HIV+ve subjects (abstract 663). In:12th Conference on Retroviruses and Opportunistic Infections. 2005 February 22\u201325; Boston MA."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002626"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.010"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000220021.64115.37"},{"key":"e_1_2_6_8_2","volume-title":"NONMEM User's Guide","author":"Beal SL","year":"1988"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03137.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011555016423"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1319"},{"key":"e_1_2_6_12_2","unstructured":"LalezariJ GoodrichJ DeJesusE LampirisH GulickR SaagM RidgwayC McHaleM Van Der RystE MayerH.Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic antiretroviral treatment experienced patients infected with CCR5\u2010tropic HIV\u20101: 24\u2010week results of a phase 2b\/3 study in the USA and Canada. In:14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA 2007 (Abstract 104bLB)."},{"key":"e_1_2_6_13_2","unstructured":"NelsonM F\u00e4tkenheuerG KonourinaI LazzarinA ClumeckN HorbanA TawadrousM SullivanJ MayerH Van Der RystE.Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic antiretroviral treatment experienced patients infected with CCR5\u2010tropic (R5) HIV\u20101 in Europe Australia and North America: 24\u2010week results. In:14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA 2007 (Abstract 104aLB)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03139.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03139.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:27:40Z","timestamp":1694615260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03139.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,10]]},"references-count":12,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03139.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03139.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,10]]}}}